Natera, Inc.
Natera, Inc. (NTRA) Stock Competitors & Peer Comparison
See (NTRA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NTRA | $138.13 | -1.42% | 18.9B | -93.97 | -$1.47 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.60% |
| TMO | $448.94 | -3.75% | 169.6B | 25.81 | $17.40 | +0.36% |
| DHR | $195.17 | -1.94% | 139.8B | 41.35 | $4.72 | +0.60% |
| IDXX | $624.19 | -2.77% | 49.9B | 52.02 | $12.00 | N/A |
| A | $113.23 | -1.44% | 32.2B | 27.83 | $4.07 | +0.86% |
| IQV | $177.49 | -3.50% | 30.2B | 25.69 | $6.91 | N/A |
| MTD | $1,221.84 | -1.78% | 25.1B | 30.95 | $39.43 | N/A |
| DGX | $173.00 | -0.16% | 19.3B | 20.71 | $8.35 | +1.80% |
| WAT | $277.72 | -1.23% | 16.5B | 25.07 | $11.08 | N/A |
Stock Comparison
NTRA vs DHR-PB Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NTRA is priced at $138.13, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NTRA's ROE is -0.18%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, NTRA is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check DHR-PB's competition here
NTRA vs TMO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, TMO has a market cap of 169.6B. Regarding current trading prices, NTRA is priced at $138.13, while TMO trades at $448.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas TMO's P/E ratio is 25.81. In terms of profitability, NTRA's ROE is -0.18%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NTRA is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check TMO's competition here
NTRA vs DHR Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DHR has a market cap of 139.8B. Regarding current trading prices, NTRA is priced at $138.13, while DHR trades at $195.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DHR's P/E ratio is 41.35. In terms of profitability, NTRA's ROE is -0.18%, compared to DHR's ROE of +0.07%. Regarding short-term risk, NTRA is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check DHR's competition here
NTRA vs IDXX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, IDXX has a market cap of 49.9B. Regarding current trading prices, NTRA is priced at $138.13, while IDXX trades at $624.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas IDXX's P/E ratio is 52.02. In terms of profitability, NTRA's ROE is -0.18%, compared to IDXX's ROE of +0.64%. Regarding short-term risk, NTRA is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check IDXX's competition here
NTRA vs A Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, A has a market cap of 32.2B. Regarding current trading prices, NTRA is priced at $138.13, while A trades at $113.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas A's P/E ratio is 27.83. In terms of profitability, NTRA's ROE is -0.18%, compared to A's ROE of +0.19%. Regarding short-term risk, NTRA is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check A's competition here
NTRA vs IQV Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, IQV has a market cap of 30.2B. Regarding current trading prices, NTRA is priced at $138.13, while IQV trades at $177.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas IQV's P/E ratio is 25.69. In terms of profitability, NTRA's ROE is -0.18%, compared to IQV's ROE of +0.20%. Regarding short-term risk, NTRA is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check IQV's competition here
NTRA vs MTD Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MTD has a market cap of 25.1B. Regarding current trading prices, NTRA is priced at $138.13, while MTD trades at $1,221.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MTD's P/E ratio is 30.95. In terms of profitability, NTRA's ROE is -0.18%, compared to MTD's ROE of +1.13%. Regarding short-term risk, NTRA is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check MTD's competition here
NTRA vs DGX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DGX has a market cap of 19.3B. Regarding current trading prices, NTRA is priced at $138.13, while DGX trades at $173.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DGX's P/E ratio is 20.71. In terms of profitability, NTRA's ROE is -0.18%, compared to DGX's ROE of +0.14%. Regarding short-term risk, NTRA is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check DGX's competition here
NTRA vs WAT Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, WAT has a market cap of 16.5B. Regarding current trading prices, NTRA is priced at $138.13, while WAT trades at $277.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas WAT's P/E ratio is 25.07. In terms of profitability, NTRA's ROE is -0.18%, compared to WAT's ROE of +0.35%. Regarding short-term risk, NTRA is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check WAT's competition here
NTRA vs ILMN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ILMN has a market cap of 14.5B. Regarding current trading prices, NTRA is priced at $138.13, while ILMN trades at $94.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ILMN's P/E ratio is 11.95. In terms of profitability, NTRA's ROE is -0.18%, compared to ILMN's ROE of +0.53%. Regarding short-term risk, NTRA is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ILMN's competition here
NTRA vs PKI Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NTRA is priced at $138.13, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PKI's P/E ratio is 41.45. In terms of profitability, NTRA's ROE is -0.18%, compared to PKI's ROE of +0.04%. Regarding short-term risk, NTRA is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check PKI's competition here
NTRA vs MEDP Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MEDP has a market cap of 12.1B. Regarding current trading prices, NTRA is priced at $138.13, while MEDP trades at $430.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MEDP's P/E ratio is 32.00. In terms of profitability, NTRA's ROE is -0.18%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, NTRA is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check MEDP's competition here
NTRA vs ICLR Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ICLR has a market cap of 12.1B. Regarding current trading prices, NTRA is priced at $138.13, while ICLR trades at $155.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ICLR's P/E ratio is 16.01. In terms of profitability, NTRA's ROE is -0.18%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, NTRA is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ICLR's competition here
NTRA vs QGEN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, QGEN has a market cap of 10.3B. Regarding current trading prices, NTRA is priced at $138.13, while QGEN trades at $47.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas QGEN's P/E ratio is 110.47. In terms of profitability, NTRA's ROE is -0.18%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, NTRA is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check QGEN's competition here
NTRA vs RVTY Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, RVTY has a market cap of 10.1B. Regarding current trading prices, NTRA is priced at $138.13, while RVTY trades at $85.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas RVTY's P/E ratio is 37.35. In terms of profitability, NTRA's ROE is -0.18%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, NTRA is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check RVTY's competition here
NTRA vs TEM Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, TEM has a market cap of 9.3B. Regarding current trading prices, NTRA is priced at $138.13, while TEM trades at $55.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas TEM's P/E ratio is -10.76. In terms of profitability, NTRA's ROE is -0.18%, compared to TEM's ROE of -5.31%. Regarding short-term risk, NTRA is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check TEM's competition here
NTRA vs EXAS Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, EXAS has a market cap of 8.8B. Regarding current trading prices, NTRA is priced at $138.13, while EXAS trades at $46.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas EXAS's P/E ratio is -8.48. In terms of profitability, NTRA's ROE is -0.18%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, NTRA is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check EXAS's competition here
NTRA vs CRL Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CRL has a market cap of 7.4B. Regarding current trading prices, NTRA is priced at $138.13, while CRL trades at $150.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CRL's P/E ratio is -250.67. In terms of profitability, NTRA's ROE is -0.18%, compared to CRL's ROE of -0.01%. Regarding short-term risk, NTRA is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CRL's competition here
NTRA vs GH Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, GH has a market cap of 5.6B. Regarding current trading prices, NTRA is priced at $138.13, while GH trades at $44.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas GH's P/E ratio is -13.31. In terms of profitability, NTRA's ROE is -0.18%, compared to GH's ROE of +2.19%. Regarding short-term risk, NTRA is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check GH's competition here
NTRA vs SYNH Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NTRA is priced at $138.13, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NTRA's ROE is -0.18%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NTRA is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check SYNH's competition here
NTRA vs RDNT Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, RDNT has a market cap of 4.1B. Regarding current trading prices, NTRA is priced at $138.13, while RDNT trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas RDNT's P/E ratio is -123.16. In terms of profitability, NTRA's ROE is -0.18%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, NTRA is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check RDNT's competition here
NTRA vs OLK Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NTRA is priced at $138.13, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas OLK's P/E ratio is -96.59. In terms of profitability, NTRA's ROE is -0.18%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NTRA is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check OLK's competition here
NTRA vs SHC Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, SHC has a market cap of 3.1B. Regarding current trading prices, NTRA is priced at $138.13, while SHC trades at $11.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas SHC's P/E ratio is 122.89. In terms of profitability, NTRA's ROE is -0.18%, compared to SHC's ROE of +0.06%. Regarding short-term risk, NTRA is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check SHC's competition here
NTRA vs TWST Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, TWST has a market cap of 1.6B. Regarding current trading prices, NTRA is priced at $138.13, while TWST trades at $25.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas TWST's P/E ratio is -17.99. In terms of profitability, NTRA's ROE is -0.18%, compared to TWST's ROE of -0.18%. Regarding short-term risk, NTRA is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check TWST's competition here
NTRA vs VIVO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, NTRA is priced at $138.13, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas VIVO's P/E ratio is 21.09. In terms of profitability, NTRA's ROE is -0.18%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, NTRA is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check VIVO's competition here
NTRA vs GRAL Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, GRAL has a market cap of 1.2B. Regarding current trading prices, NTRA is priced at $138.13, while GRAL trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas GRAL's P/E ratio is -0.56. In terms of profitability, NTRA's ROE is -0.18%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, NTRA is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check GRAL's competition here
NTRA vs NEOG Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, NEOG has a market cap of 1B. Regarding current trading prices, NTRA is priced at $138.13, while NEOG trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas NEOG's P/E ratio is -0.95. In terms of profitability, NTRA's ROE is -0.18%, compared to NEOG's ROE of -0.41%. Regarding short-term risk, NTRA is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check NEOG's competition here
NTRA vs OPK Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, OPK has a market cap of 1B. Regarding current trading prices, NTRA is priced at $138.13, while OPK trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas OPK's P/E ratio is -4.88. In terms of profitability, NTRA's ROE is -0.18%, compared to OPK's ROE of -0.13%. Regarding short-term risk, NTRA is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check OPK's competition here
NTRA vs CDNA Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CDNA has a market cap of 729.4M. Regarding current trading prices, NTRA is priced at $138.13, while CDNA trades at $13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CDNA's P/E ratio is 11.70. In terms of profitability, NTRA's ROE is -0.18%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, NTRA is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CDNA's competition here
NTRA vs FLGT Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, FLGT has a market cap of 632.7M. Regarding current trading prices, NTRA is priced at $138.13, while FLGT trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas FLGT's P/E ratio is -12.45. In terms of profitability, NTRA's ROE is -0.18%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, NTRA is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check FLGT's competition here
NTRA vs GRALV Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NTRA is priced at $138.13, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas GRALV's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to GRALV's ROE of N/A. Regarding short-term risk, NTRA is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check GRALV's competition here
NTRA vs CSTL Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CSTL has a market cap of 573.2M. Regarding current trading prices, NTRA is priced at $138.13, while CSTL trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CSTL's P/E ratio is -104.00. In terms of profitability, NTRA's ROE is -0.18%, compared to CSTL's ROE of -0.02%. Regarding short-term risk, NTRA is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CSTL's competition here
NTRA vs MYGN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MYGN has a market cap of 522.6M. Regarding current trading prices, NTRA is priced at $138.13, while MYGN trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MYGN's P/E ratio is -5.06. In terms of profitability, NTRA's ROE is -0.18%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, NTRA is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check MYGN's competition here
NTRA vs LAB Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, LAB has a market cap of 486.2M. Regarding current trading prices, NTRA is priced at $138.13, while LAB trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas LAB's P/E ratio is -4.00. In terms of profitability, NTRA's ROE is -0.18%, compared to LAB's ROE of -0.28%. Regarding short-term risk, NTRA is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check LAB's competition here
NTRA vs CO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NTRA is priced at $138.13, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CO's P/E ratio is 5.06. In terms of profitability, NTRA's ROE is -0.18%, compared to CO's ROE of +0.11%. Regarding short-term risk, NTRA is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CO's competition here
NTRA vs PSNL Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PSNL has a market cap of 389.1M. Regarding current trading prices, NTRA is priced at $138.13, while PSNL trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PSNL's P/E ratio is -3.41. In terms of profitability, NTRA's ROE is -0.18%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, NTRA is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check PSNL's competition here
NTRA vs FLDM Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NTRA is priced at $138.13, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NTRA's ROE is -0.18%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, NTRA is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check FLDM's competition here
NTRA vs STIM Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, STIM has a market cap of 280.7M. Regarding current trading prices, NTRA is priced at $138.13, while STIM trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas STIM's P/E ratio is -3.22. In terms of profitability, NTRA's ROE is -0.18%, compared to STIM's ROE of -1.94%. Regarding short-term risk, NTRA is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check STIM's competition here
NTRA vs XGN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, XGN has a market cap of 196.1M. Regarding current trading prices, NTRA is priced at $138.13, while XGN trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas XGN's P/E ratio is -10.01. In terms of profitability, NTRA's ROE is -0.18%, compared to XGN's ROE of -1.36%. Regarding short-term risk, NTRA is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check XGN's competition here
NTRA vs ACRS Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ACRS has a market cap of 167.8M. Regarding current trading prices, NTRA is priced at $138.13, while ACRS trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ACRS's P/E ratio is -0.97. In terms of profitability, NTRA's ROE is -0.18%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, NTRA is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ACRS's competition here
NTRA vs NEO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, NEO has a market cap of 141.8M. Regarding current trading prices, NTRA is priced at $138.13, while NEO trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas NEO's P/E ratio is -6.70. In terms of profitability, NTRA's ROE is -0.18%, compared to NEO's ROE of -0.12%. Regarding short-term risk, NTRA is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check NEO's competition here
NTRA vs MDXH Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MDXH has a market cap of 136.1M. Regarding current trading prices, NTRA is priced at $138.13, while MDXH trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MDXH's P/E ratio is -2.64. In terms of profitability, NTRA's ROE is -0.18%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, NTRA is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check MDXH's competition here
NTRA vs GTH Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NTRA is priced at $138.13, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas GTH's P/E ratio is -1.11. In terms of profitability, NTRA's ROE is -0.18%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NTRA is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check GTH's competition here
NTRA vs GENE Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NTRA is priced at $138.13, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas GENE's P/E ratio is -38.25. In terms of profitability, NTRA's ROE is -0.18%, compared to GENE's ROE of -3.62%. Regarding short-term risk, NTRA is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check GENE's competition here
NTRA vs PRE Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PRE has a market cap of 102.7M. Regarding current trading prices, NTRA is priced at $138.13, while PRE trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PRE's P/E ratio is -2.07. In terms of profitability, NTRA's ROE is -0.18%, compared to PRE's ROE of -0.28%. Regarding short-term risk, NTRA is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check PRE's competition here
NTRA vs SERA Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, SERA has a market cap of 100.9M. Regarding current trading prices, NTRA is priced at $138.13, while SERA trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas SERA's P/E ratio is -2.93. In terms of profitability, NTRA's ROE is -0.18%, compared to SERA's ROE of -0.51%. Regarding short-term risk, NTRA is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check SERA's competition here
NTRA vs PRENW Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PRENW has a market cap of 96.9M. Regarding current trading prices, NTRA is priced at $138.13, while PRENW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PRENW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, NTRA is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check PRENW's competition here
NTRA vs ATLN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ATLN has a market cap of 92.5M. Regarding current trading prices, NTRA is priced at $138.13, while ATLN trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ATLN's P/E ratio is -0.41. In terms of profitability, NTRA's ROE is -0.18%, compared to ATLN's ROE of -42.96%. Regarding short-term risk, NTRA is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ATLN's competition here
NTRA vs NOTV Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, NOTV has a market cap of 76.3M. Regarding current trading prices, NTRA is priced at $138.13, while NOTV trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas NOTV's P/E ratio is -0.71. In terms of profitability, NTRA's ROE is -0.18%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, NTRA is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check NOTV's competition here
NTRA vs VNRX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, VNRX has a market cap of 69.7M. Regarding current trading prices, NTRA is priced at $138.13, while VNRX trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas VNRX's P/E ratio is -2.48. In terms of profitability, NTRA's ROE is -0.18%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, NTRA is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check VNRX's competition here
NTRA vs BDSX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BDSX has a market cap of 57.2M. Regarding current trading prices, NTRA is priced at $138.13, while BDSX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BDSX's P/E ratio is -1.44. In terms of profitability, NTRA's ROE is -0.18%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, NTRA is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check BDSX's competition here
NTRA vs STRRP Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, STRRP has a market cap of 29.2M. Regarding current trading prices, NTRA is priced at $138.13, while STRRP trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas STRRP's P/E ratio is -4.54. In terms of profitability, NTRA's ROE is -0.18%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, NTRA is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check STRRP's competition here
NTRA vs AKU Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NTRA is priced at $138.13, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas AKU's P/E ratio is -0.13. In terms of profitability, NTRA's ROE is -0.18%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NTRA is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check AKU's competition here
NTRA vs DRIO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DRIO has a market cap of 23.5M. Regarding current trading prices, NTRA is priced at $138.13, while DRIO trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DRIO's P/E ratio is -0.96. In terms of profitability, NTRA's ROE is -0.18%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, NTRA is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check DRIO's competition here
NTRA vs PRPO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PRPO has a market cap of 22M. Regarding current trading prices, NTRA is priced at $138.13, while PRPO trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PRPO's P/E ratio is -7.08. In terms of profitability, NTRA's ROE is -0.18%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, NTRA is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check PRPO's competition here
NTRA vs CEMI Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NTRA is priced at $138.13, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NTRA's ROE is -0.18%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NTRA is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check CEMI's competition here
NTRA vs ENZ Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NTRA is priced at $138.13, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NTRA's ROE is -0.18%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, NTRA is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ENZ's competition here
NTRA vs PMD Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, NTRA is priced at $138.13, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas PMD's P/E ratio is -5.24. In terms of profitability, NTRA's ROE is -0.18%, compared to PMD's ROE of -0.33%. Regarding short-term risk, NTRA is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check PMD's competition here
NTRA vs ME Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, NTRA is priced at $138.13, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ME's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.18%, compared to ME's ROE of -5.52%. Regarding short-term risk, NTRA is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ME's competition here
NTRA vs INBS Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, INBS has a market cap of 11.6M. Regarding current trading prices, NTRA is priced at $138.13, while INBS trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas INBS's P/E ratio is -1.17. In terms of profitability, NTRA's ROE is -0.18%, compared to INBS's ROE of -1.72%. Regarding short-term risk, NTRA is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check INBS's competition here
NTRA vs BGLC Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BGLC has a market cap of 10.2M. Regarding current trading prices, NTRA is priced at $138.13, while BGLC trades at $5.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BGLC's P/E ratio is -4.79. In terms of profitability, NTRA's ROE is -0.18%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, NTRA is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check BGLC's competition here
NTRA vs BNGO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BNGO has a market cap of 10.1M. Regarding current trading prices, NTRA is priced at $138.13, while BNGO trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BNGO's P/E ratio is -0.06. In terms of profitability, NTRA's ROE is -0.18%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, NTRA is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check BNGO's competition here
NTRA vs CNTG Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, NTRA is priced at $138.13, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NTRA's ROE is -0.18%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NTRA is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CNTG's competition here
NTRA vs BIAFW Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BIAFW has a market cap of 8.6M. Regarding current trading prices, NTRA is priced at $138.13, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BIAFW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, NTRA is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check BIAFW's competition here
NTRA vs TRIB Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, TRIB has a market cap of 8.6M. Regarding current trading prices, NTRA is priced at $138.13, while TRIB trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas TRIB's P/E ratio is -0.46. In terms of profitability, NTRA's ROE is -0.18%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, NTRA is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check TRIB's competition here
NTRA vs BIAF Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BIAF has a market cap of 8.2M. Regarding current trading prices, NTRA is priced at $138.13, while BIAF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BIAF's P/E ratio is -0.41. In terms of profitability, NTRA's ROE is -0.18%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, NTRA is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check BIAF's competition here
NTRA vs ADVB Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ADVB has a market cap of 7.8M. Regarding current trading prices, NTRA is priced at $138.13, while ADVB trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ADVB's P/E ratio is -2.26. In terms of profitability, NTRA's ROE is -0.18%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, NTRA is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ADVB's competition here
NTRA vs ISPC Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, ISPC has a market cap of 6.7M. Regarding current trading prices, NTRA is priced at $138.13, while ISPC trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas ISPC's P/E ratio is -0.14. In terms of profitability, NTRA's ROE is -0.18%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, NTRA is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check ISPC's competition here
NTRA vs BNR Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BNR has a market cap of 6.6M. Regarding current trading prices, NTRA is priced at $138.13, while BNR trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BNR's P/E ratio is -1.91. In terms of profitability, NTRA's ROE is -0.18%, compared to BNR's ROE of -0.39%. Regarding short-term risk, NTRA is more volatile compared to BNR. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check BNR's competition here
NTRA vs STRR Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, STRR has a market cap of 6.5M. Regarding current trading prices, NTRA is priced at $138.13, while STRR trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas STRR's P/E ratio is -0.67. In terms of profitability, NTRA's ROE is -0.18%, compared to STRR's ROE of -0.24%. Regarding short-term risk, NTRA is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check STRR's competition here
NTRA vs MYNZ Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MYNZ has a market cap of 5.7M. Regarding current trading prices, NTRA is priced at $138.13, while MYNZ trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MYNZ's P/E ratio is -0.07. In terms of profitability, NTRA's ROE is -0.18%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, NTRA is more volatile compared to MYNZ. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check MYNZ's competition here
NTRA vs NVTA Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, NTRA is priced at $138.13, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas NVTA's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.18%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, NTRA is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check NVTA's competition here
NTRA vs LMDX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NTRA is priced at $138.13, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NTRA's ROE is -0.18%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NTRA is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check LMDX's competition here
NTRA vs LMDXW Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NTRA is priced at $138.13, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.18%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NTRA is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check LMDXW's competition here
NTRA vs NDRA Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, NDRA has a market cap of 3.9M. Regarding current trading prices, NTRA is priced at $138.13, while NDRA trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas NDRA's P/E ratio is 0.01. In terms of profitability, NTRA's ROE is -0.18%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, NTRA is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check NDRA's competition here
NTRA vs CHEK Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, CHEK has a market cap of 3.5M. Regarding current trading prices, NTRA is priced at $138.13, while CHEK trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas CHEK's P/E ratio is -0.28. In terms of profitability, NTRA's ROE is -0.18%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, NTRA is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check CHEK's competition here
NTRA vs DMTK Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NTRA is priced at $138.13, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NTRA's ROE is -0.18%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, NTRA is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check DMTK's competition here
NTRA vs AWH Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, NTRA is priced at $138.13, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas AWH's P/E ratio is -0.09. In terms of profitability, NTRA's ROE is -0.18%, compared to AWH's ROE of +4.66%. Regarding short-term risk, NTRA is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check AWH's competition here
NTRA vs SQL Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NTRA is priced at $138.13, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas SQL's P/E ratio is -0.40. In terms of profitability, NTRA's ROE is -0.18%, compared to SQL's ROE of +10.89%. Regarding short-term risk, NTRA is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check SQL's competition here
NTRA vs APDN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, APDN has a market cap of 2.2M. Regarding current trading prices, NTRA is priced at $138.13, while APDN trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas APDN's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to APDN's ROE of -2.81%. Regarding short-term risk, NTRA is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check APDN's competition here
NTRA vs HTGM Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NTRA is priced at $138.13, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.18%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NTRA is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check HTGM's competition here
NTRA vs BIOC Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NTRA is priced at $138.13, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NTRA's ROE is -0.18%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NTRA is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check BIOC's competition here
NTRA vs TTOO Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, TTOO has a market cap of 434.7K. Regarding current trading prices, NTRA is priced at $138.13, while TTOO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas TTOO's P/E ratio is -0.52. In terms of profitability, NTRA's ROE is -0.18%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, NTRA is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check TTOO's competition here
NTRA vs OPGN Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, OPGN has a market cap of 392.7K. Regarding current trading prices, NTRA is priced at $138.13, while OPGN trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas OPGN's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, NTRA is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check OPGN's competition here
NTRA vs SQLLW Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, NTRA is priced at $138.13, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, NTRA's ROE is -0.18%, compared to SQLLW's ROE of -42.96%. Regarding short-term risk, NTRA is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check SQLLW's competition here
NTRA vs DHR-PA Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NTRA is priced at $138.13, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NTRA's ROE is -0.18%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, NTRA is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check DHR-PA's competition here
NTRA vs MEUSW Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NTRA is priced at $138.13, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.18%, compared to MEUSW's ROE of -5.52%. Regarding short-term risk, NTRA is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for NTRA.Check MEUSW's competition here
NTRA vs OCDX Comparison August 2025
NTRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 18.9B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NTRA is priced at $138.13, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -93.97, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NTRA's ROE is -0.18%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NTRA is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for NTRA.Check OCDX's competition here